Experimental drug combo takes on tough cancers
NCT ID NCT05407675
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. The study is now complete, but results on effectiveness are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Hackensack, New Jersey, 07601, United States
-
Local Institution - 0003
Houston, Texas, 77030, United States
-
Local Institution - 0005
Ottawa, Ontario, K1H 8L6, Canada
-
Local Institution - 0006
Toronto, Ontario, M5G 2M9, Canada
-
Local Institution - 0007
Edmonton, Alberta, T6G 1Z2, Canada
-
Local Institution - 0010
Boston, Massachusetts, 02215, United States
-
Local Institution - 0011
Hamilton, Ontario, L8V5C2, Canada
-
Local Institution - 0012
Basel, 4031, Switzerland
-
Local Institution - 0014
Villejuif, Paris, 94800, France
-
Local Institution - 0015
Bordeaux, Aquitaine, 33076, France
-
Local Institution - 0018
Marseille, 13385, France
-
Local Institution - 0019
Toulouse, 31059, France
-
Local Institution - 0020
Geneva, 1205, Switzerland
-
Local Institution - 0021
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Local Institution - 0022
Madrid, 28040, Spain
-
Local Institution - 0023
Madrid, 28050, Spain
-
Local Institution - 0024
Málaga, Andalusia, 29010, Spain
-
Local Institution - 0025
Madrid, Madrid, Comunidad de, 28009, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986408 (an experimental drug) combined with nivolumab (Opdivo) and/or ipilimumab (Yervoy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that haven't responded to other therapies.
What could go wrong
This is an early-phase trial focused on safety and dosing, not yet on effectiveness. The combination may cause severe side effects, and it's unknown if it will shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.